Sees FY23 consolidated revenue growth of 7%-10% compared to FY22. The company continues to expect Core Illumina revenue growth of 6% to 9% compared to fiscal year 2022. GRAIL revenue is still expected to be in the range of $90M-$110M. Sees FY23 GAAP diluted EPS (28c)-(3c). The GAAP and non-GAAP diluted EPs ranges continue to assume that the existing R&D capitalization requirements are not repealed in FY23 and, as a result, reflect a tax expense impact of approximately $75M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ILMN:
- Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth
- Illumina options imply 5.4% move in share price post-earnings
- Icahn issues letter to Illumina, accuses of ‘attempt to disenfranchise’ holders
- Illumina issues letter to shareholders regarding board nomination vote
- Illumina partners with Henry Ford Health on genomic testing